Earnings reports are critical indicators of a company's financial health and often result in significant stock price movements. Fulcrum Therapeutics' better-than-expected GAAP EPS for Q1 directly impacts investor sentiment and stock valuation, likely leading to increased buying activity and a positive short-term price movement.